PHARMACOLOGY OF COGNITION IN SCHIZOTYPAL PERSONALITY

精神分裂型人格的认知药理学

• 批准号: 7953656
• 负责人: Larry J Siever
• 金额: $ 0.15万
• 依托单位: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-03-01 至 2009-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7953656
• 关键词: Accounting; Activities of Daily Living; Clinical; Clinical Research; Cognition; Computer Retrieval of Information on Scientific Projects Database; Episodic memory; Funding; Grant; Guanfacine; Impairment; Institution; Maintenance; Measures; Memory; Patients; Performance; Personality; Pharmacology; Process; Research; Research Personnel; Resources; Schizophrenia; Schizotypal Personality Disorder; Short-Term Memory; Source; Stimulus; Symptoms; Testing; Time; United States National Institutes of Health; Visual attention; Visuospatial; base; executive function; improved

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Hypothesis: 1) SPD patients will demonstrate impairment across verbal and visuospatial stimuli in several different tests sensitive to central executive functions (i.e., maintenance plus manipulation, dual-task processing: time sharing, and context processing) that is disproportionate to their maintenance-only performance, similar to previous results in schizophrenia. 2) These deficits will not be accounted for by visual attention/perceptual integration deficits or clinical symptoms. 3) Performance-based measures of functional capacity will be impaired in SPD and performance on these tasks will be related to central executive functioning, including context processing, dual-task time sharing, and maintenance and manipulation working memory. 4) Guanfacine will improve performance in SPD patients only on the maintenance plus manipulation task, context processing, dual-task time sharing, as well as on the functional capacity measures. 5) No significant improvement with guanfacine will be seen on maintenance only working memory, simple memory span, and measures of episodic memory.

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 假设： 1)SPD患者将在几种不同的测试中表现出跨语言和视觉空间刺激的损害，这些测试对中央执行功能(即维持加操纵、双重任务处理：分时处理和上下文处理)敏感，与他们仅维持的表现不成比例，类似于以前在精神分裂症中的结果。 2)这些缺陷不会由视觉注意/知觉整合缺陷或临床症状来解释。 3)在SPD中，基于绩效的功能能力测量将受到损害，这些任务的绩效将与中央执行功能有关，包括上下文处理、双任务分时以及维护和操纵工作记忆。 4)只有在维持加操作任务、情境加工、双任务分时以及功能容量测量上，金刚烷才能改善SPD患者的成绩。 5)仅维持工作记忆、简单记忆广度和情景记忆的测量结果显示，仅工作记忆的维持、简单记忆广度和情景记忆的测量没有明显的改善。